Norges Bank Adaptive Biotechnologies Corp Transaction History

Norges Bank

$716 Trillion
Q3 2024

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$3.46 - $5.33 $2.38 Million - $3.67 Million	689,150 New	689,150 $3.38 Million
Q3 2023 Nov 13, 2024	BUY	$5.07 - $8.44 $4.09 Million - $6.8 Million	805,972 New	805,972 $4.39 Million
Q3 2023 Nov 13, 2023	SELL	$5.07 - $8.44 $5.48 Million - $9.12 Million	-1,080,221 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$6.19 - $8.78 $4.99 Million - $7.08 Million	805,972 New	805,972 $5.41 Million
Q2 2023 Aug 14, 2023	SELL	$6.19 - $8.78 $6.97 Million - $9.88 Million	-1,125,675 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$7.8 - $10.11 $6.29 Million - $8.15 Million	805,972 New	805,972 $7.12 Million
Q4 2022 Feb 14, 2023	BUY	$6.26 - $9.34 $6.76 Million - $10.1 Million	1,080,221 New	1,080,221 $8.25 Million
Q3 2022 Nov 13, 2023	BUY	$6.5 - $12.67 $7.02 Million - $13.7 Million	1,080,221 New	1,080,221 $7.69 Million
Q2 2022 Aug 14, 2023	BUY	$6.4 - $14.73 $7.2 Million - $16.6 Million	1,125,675 New	1,125,675 $9.11 Million
Q1 2022 May 12, 2023	SELL	$10.12 - $28.9 $149,290 - $426,332	-14,752 Reduced 1.37%	1,065,469 $14.8 Million
Q1 2022 May 09, 2022	SELL	$10.12 - $28.9 $10.5 Million - $30 Million	-1,038,623 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$25.17 - $36.85 $26.1 Million - $38.3 Million	1,038,623 New	1,038,623 $29.1 Million
Q3 2021 Nov 14, 2022	BUY	$30.02 - $39.87 $29.1 Million - $38.7 Million	969,709 New	969,709 $33 Million
Q3 2021 Nov 05, 2021	SELL	$30.02 - $39.87 $27.5 Million - $36.5 Million	-914,879 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$32.22 - $44.59 $29.5 Million - $40.8 Million	914,879 New	914,879 $37.4 Million
Q2 2021 Aug 10, 2021	SELL	$32.22 - $44.59 $21.6 Million - $29.9 Million	-669,842 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$37.26 - $67.74 $25 Million - $45.4 Million	669,842 New	669,842 $27 Million
Q1 2021 May 07, 2021	SELL	$37.26 - $67.74 $30.8 Million - $56.1 Million	-827,880 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$45.01 - $65.47 $37.3 Million - $54.2 Million	827,880 New	827,880 $49 Million
Q4 2020 Feb 10, 2021	SELL	$45.01 - $65.47 $41.7 Million - $60.6 Million	-925,761 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$35.79 - $48.81 $33.1 Million - $45.2 Million	925,761 New	925,761 $45 Million
Q3 2020 Nov 10, 2020	SELL	$35.79 - $48.81 $2.37 Million - $3.23 Million	-66,269 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$24.95 - $48.38 $1.65 Million - $3.21 Million	66,269 New	66,269 $3.21 Million
Q2 2020 Aug 07, 2020	SELL	$24.95 - $48.38 $1.65 Million - $3.21 Million	-66,269 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$16.96 - $34.16 $1.12 Million - $2.26 Million	66,269 New	66,269 $1.84 Million
Q1 2020 May 08, 2020	SELL	$16.96 - $34.16 $275,922 - $555,749	-16,269 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$24.56 - $32.8 $399,566 - $533,623	16,269 New	16,269 $487,000
Q4 2019 Feb 12, 2020	SELL	$24.56 - $32.8 $1.11 Million - $1.48 Million	-45,000 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$30.31 - $53.51 $1.36 Million - $2.41 Million	45,000 New	45,000 $1.39 Million
Q3 2019 Nov 08, 2019	SELL	$30.31 - $53.51 $1.36 Million - $2.41 Million	-45,000 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$40.3 - $48.3 $1.81 Million - $2.17 Million	45,000 New	45,000 $2.17 Million

Others Institutions Holding ADPT

# of Institutions

202

Shares Held

146M

Call Options Held

68.8K

Put Options Held

42.5K

Viking Global Investors LP

30M
Shares

$178 Million
0.59% of portfolio
Rubric Capital Management LP New York, NY

14.4M
Shares

$85.5 Million
2.05% of portfolio
Black Rock Inc. New York, NY

11.7M
Shares

$69.3 Million
0.0% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

11.6M
Shares

$68.9 Million
0.56% of portfolio
Vanguard Group Inc Valley Forge, PA

10.6M
Shares

$63.2 Million
0.0% of portfolio

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account